je.st
news
Tag: lymphoma
Bio-Path Holdings To Initiate Development Of Liposomal Bcl-2 In Follicular Lymphoma
2014-12-29 02:22:44| drugdiscoveryonline Home Page
Bio-Path Holdings, Inc., (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, recently announced that it has initiated development of Liposomal Bcl-2 as a treatment for follicular lymphoma
Tags: development
holdings
initiate
lymphoma
Seattle Genetics Makes Case for Expanded Use of Adcetris as Lymphoma Maintenance Therapy
2014-12-07 16:25:51| Biotech - Topix.net
Your browser is not supported. Please upgrade to one of the following browsers: Google Chrome Mozilla Firefox Apple Safari Microsoft Internet Explorer 8+ You may proceed to the site by clicking here , however some pages might not work correctly.
Tags: case
makes
maintenance
expanded
Data Investigating KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting
2014-12-06 19:00:00| Merck.com - Corporate News
Dateline City: SAN FRANCISCO Overall Response Rate of 66 Percent Observed in KEYTRUDA-treated Patients Whose Cancer Progressed on Brentuximab Vedotin Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-087) SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, achieved an overall response rate of 66 percent, as assessed by International Harmonization Project response criteria (n=19/29: 95% CI, 46-82), in transplant-ineligible and failure patients with relapsed/refractory classical Hodgkin Lymphoma (cHL) whose disease progressed on or after treatment with brentuximab vedotin. Language: English Contact: Media:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
presented
meeting
annual
Heart-transplant recipient beats lymphoma
2014-11-27 04:30:04| Apparel - Topix.net
In the nearly 22 years of his son's life, Doug Carter recalls five moments in the last year so clearly. The first two came within a span of 12 days, when he received a call about a heart being available for his son Shaw Carter.
Tags: recipient
beats
lymphoma
New Studies Investigating the Use of KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
2014-11-06 15:08:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. By Year End, Data on KEYTRUDA in Seven Tumor Types Will Have Been Presented WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA (pembrolizumab) the companys anti-PD-1 therapy in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestor:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more